01. Gene therapy Boulikas.pdf - Gene therapy & Molecular Biology

More documents

Recommendations

Info

Duke RC, Ojcius DM, and Young JD-E (1996) Cell suicide in health and disease. Scientifc Amer 275, 80-87. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, Breitman ML (1994) Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8, 1897-1909. Dunbar C and Kohn D (1996) Retroviral mediated transfer of the cDNA for human glucocerebrosidase into hematopoietic stem cells of patients with Gaucher disease. A phase I study. Hum Gene Ther 7, 231-253. Dunlap DD, Maggi A, Soria MR, Monaco L (1997) Nanoscopic structure of DNA condensed for gene delivery. Nucleic Acids Res 25, 3095-3101. Dupuit F, Chinet T, Zahm JM, Pierrot D, Hinnrasky J, Kaplan H, Bonnet N, Puchelle E (1997) Induction of a cAMPstimulated chloride secretion in regenerating poorly differentiated airway epithelial cells by adenovirus-mediated CFTR gene transfer. Hum Gene Ther 8, 1439-1450. During MJ, Naegele JR, O'Malley KL, Geller AI (1994) Longterm behavioral recovery in Parkinsonian rats by an HSV Vector expressing tyrosine hydroxylase. Science 266, 1399- 1403. Dutta A, Ruppert JM, Aster JC and Winchester E (1993) Inhibition of DNA replication factor RPA by p53. Nature 365: 79-82. Dwarki VJ, Belloni P, Nijjar T, Smith J, Couto L, Rabier M, Clift S, Berns A, and Cohen LK (1995) Gene therapy for hemophilia A: Production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA 92, 1023-1027. Dyson, N., Howley, P.M., Münger, K. and Harlow, E. (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934-937. Ealovega MW, McGinnis PK, Sumantran VN, Clarke MF, Wicha MS (1996) bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice. Cancer Res 56, 1965-1969. Eastham JA, Chen S-H, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SLC, and Thompson TC (1996) Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 7, 515-523. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang W-W, Harper JW, and Thompson TC (1995) In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55, 5151- 5155. Ebbinghaus SW, Vigneswaran N, Miller CR, Chee-Awai RA, Mayfield CA, Curiel DT, Miller DM (1996) Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus-polylysine complexes. Gene Ther 3, 287-297. Eckert HG, Stockschlader M, Just U, Hegewisch-Becker S, Grez M, Uhde A, Zander A, Ostertag W, Baum C (1996) Highdose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral vectors. Blood 88, 3407-3415. Boulikas: An overview on gene therapy 138 Einerhand MP, Antoniou M, Zolotukhin S, Muzyczka N, Berns KI, Grosveld F, Valerio D (1995) Regulated high-level human β-globin gene expression in erythroid cells following recombinant adeno-associated virus-mediated gene transfer. Gene Ther 2, 336-343. El Ouahabi A, Thiry M, Pector V, Fuks R, Ruysschaert JM, Vandenbranden M (1997) The role of endosome destabilizing activity in the gene transfer process mediated by cationic lipids. FEBS Lett 414, 187-192. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Nature Genet 1, 45-49. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M (1989) Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86, 8763-8767. Elshami AA, Cook JW, Amin KM, Choi H, Park JY, Coonrod L, Sun J, Molnar-Kimber K, Wilson JM, Kaiser LR, Albelda SM (1997) The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo. Cancer Gene Ther 4, 213-221. Emoto Y, Manome Y, Meinhardt G, Kisaki H, Kharbanda S, Robertson M, Ghayur T, Wong WW, Kamen R, Weichselbaum R, et al (1995) Proteolytic activation of protein kinase C δ by an ICE-like protease in apoptotic cells. EMBO J 14, 6148-6156. Endicott JA and Ling V (1989) The biochemistry of Pglycoprotein-mediated multidrug resistance. Annu Rev Biochem 58, 137-171. Enomaa N, Danos O, Peltonen L, and Jalanko A (1995) Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer. Hum Gene Ther 6, 723-731. Evans CH and Robbins PD (1996) Pathways to gene therapy in rheumatoid arthritis. Curr Opin Rheumatol 8, 230-234. Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, Barranger JA, Elders EM, Gay S, Tomaino MM, Wasko MC, Watkins SC, Whiteside TL, Glorioso JC, Lotze MT, Wright TM (1996) Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 7, 1261-1280. Fang B, Eisensmith RC, Wang H, Kay MA, Cross RE, Landen CN, Gordon G, Bellinger DA, Read MS, Hu PC, Brinkhous KM, and Woo SLC (1995) Gene therapy for hemophilia B: Host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 6, 1039-1044. Fardel O, Escande F, Drenou B, Le Bescot J, Rault B, and Fauchet R (1995) Expression of P-glycoprotein in multidrugresistant human leukemia K562 cells during erythroid differentiation. Int J Oncol 7, 377-381.
Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C (1992) Wild-type p53 activates transcription in vitro. Nature 358, 83-86. Fasbender A, Zabner J, Chillon M, Moninger TO, Puga AP, Davidson BL, Welsh MJ (1997) Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 272, 6479-6489. Fassati A, Wells DJ, Walsh FS, Dickson G (1995) Efficiency of in vivo gene transfer using murine retroviral vectors is straindependent in mice. Hum Gene Ther 6, 1177-1183. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403. Federspiel MJ, Swing DA, Eagleson B, Reid SW, Hughes SH (1996) Expression of transduced genes in mice generated by infecting blastocysts with avian leukosis virus-based retroviral vectors. Proc Natl Acad Sci USA 93, 4931-4936. Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, Ramsey P, Martin M, Felgner PL (1994) Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 269, 2550-2561. Felgner PL and Ringold GM (1991) Cationic liposome-mediated transfection. Nature 337, 387-388. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, and Danielsen M (1987) Lipofection: a highly efficient, lipid-mediated DNAtransfection procedure. Proc Natl Acad Sci USA 84, 7413- 7417. Felgner PL, Rhodes G (1991) Gene therapeutics. Nature 349, 351-352. Fender P, Ruigrok RW, Gout E, Buffet S, Chroboczek J (1997) Adenovirus dodecahedron, a new vector for human gene transfer. Nat Biotechnol 15, 52-56. Feng M, Jackson WH, Goldman CK, Rancourt C, Wang M, Dusing SK, Siegal G, and Curiel DT (1997) Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nature Biotechnol 15, 866-870. Fenjves ES, Gordon DA, Persing LK, Williams DL, Taichman LB (1989) Systemic distribution of apolipoprotein E secreted by grafts of epidermal keratinocytes: Implications for epidermal function and gene therapy. Proc Natl Acad Sci USA 86, 8803-8807. Fernex C, Dubreuil P, Mannoni P, Bagnis C (1997) Cre/loxPmediated excision of a neomycin resistance expression unit from an integrated retroviral vector increases long terminal repeat-driven transcription in human hematopoietic cells. J Virol 71, 7533-7540. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442. Ferrari G, Rossini S, Giavazzi R, Maggioni D, Nobili N, Soldati M, Ungers G, Mavilio F, Gilboa E, Bordignon C (1991) An Gene Therapy and Molecular Biology Vol 1, page 139 139 in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science 251, 1363-1366. Ferrari S, Moro E, Pettenazzo A, Behr J-P, Zacchello F, and Scarpa M (1997) ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo. Gene Therapy 4, 1100-1106. Field AK, Davies ME, DeWitt, Perry HC, Liou R, Germershausen J, Karkas JD, Ashton WT, Johnston DBR, Tolman RL (1983) 9-{[2-Hydroxy-1-(hydroxymethyl) ethoxy]methyl} guanine: A selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 80, 4139- 4143. Field SJ, Tsai F-Y, Kuo F, Zubiaga AM, Kaelin WGJr, Livingston DM, Orkin SH, and Greenberg ME (1996) E2F-1 functions in mice to promote apoptosis and suppresses proliferation. Cell 85, 549-561. Fields S and Jang SK (1990) Presence of a potent transcription activating sequence in the p53 protein. Science 249: 1046- 1049. Filion MC and Phillips NC (1997) Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1329, 345-356. Finke S, Trojaneck B, Moller P, Schadendorf D, Neubauer A, Huhn D, Schmidt-Wolf IG (1997) Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interleukin-7 gene to autologous and allogeneic immunologic effector cells. Cancer Gene Ther 4, 260-268. Finlay CA, Hinds PW, Levine AJ (1989) The p53 protooncogene can act as a suppressor of transformation. Cell 57, 1083-1093. Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM (1996) Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217, 11-22. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, Pathak R, Raper SE, Wilson JM (1997) Recombinant adenoassociated virus for muscle directed gene therapy. Nat Med 3, 306-312. Fisher LJ, Jinnah HA, Kale LC, Higgins GA, Gage FH (1991) Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 6, 371-380. Flamme I, von Reutern M, Drexler HC, Syed-Ali S, Risau W (1995) Overexpression of vascular endothelial growth factor in the avian embryo induces hypervascularization and increased vascular permeability without alterations of embryonic pattern formation. Dev Biol 171, 399-414. Flotte TR, Barraza-Ortiz X, Solow R, Afione SA, Carter BJ, Guggino WB (1995) An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction. Gene Ther 2, 29-37. Flugelman MY, Jaklitch MT, Newman KD, Casscells W, Bratthauer GL, and Dichek DA (1992) Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation 85, 1110-1117. Folkman J and D’Amore PA (1996) Blood vessel formation: what is its molecular basis? Cell 87, 1153-1155.
Page 1 and 2:
Gene Ther Mol Biol Vol 1, 1-172. Ma
Page 3 and 4:
I. Introduction Monumental progress
Page 5 and 6:
The use of retroviral vectors in hu
Page 7 and 8:
displaying the cleavable EGF domain
Page 9 and 10:
molecules in the nucleus (Lowe and
Page 11 and 12:
sensitive mutations which allow pro
Page 13 and 14:
processed as described in panel A s
Page 15 and 16:
On the contrary, the payload capaci
Page 17 and 18:
in K562 human erythroleukemia cells
Page 19 and 20:
defective HSV virus (DeLuca and Sch
Page 21 and 22:
complex into the cytosol from the e
Page 23 and 24:
Gene Therapy and Molecular Biology
Page 25 and 26:
delivered by Sendai virus-liposome
Page 27 and 28:
plasmids with the cell surface, tra
Page 29 and 30:
infected by adenovirus alone; infec
Page 31 and 32:
Page 33 and 34:
B. Transcription factor binding sit
Page 35 and 36:
A closely related family of ubiquit
Page 37 and 38:
cells. I-CreI is a member of this c
Page 39 and 40:
Page 41 and 42:
C. Considerations of chromatin stru
Page 43 and 44:
Page 45 and 46:
A. The molecular basis of cancer im
Page 47 and 48:
fragments, or heat shock proteins c
Page 49 and 50:
ecombinant vaccinia virus expressin
Page 51 and 52:
HIV-1 envelope DNA construct develo
Page 53 and 54:
inding sites A GYYY oriented in opp
Page 55 and 56:
Page 57 and 58:
Prives, 1994). Whereas the wild-typ
Page 59 and 60:
mutant p53 (mutations on p53 are wi
Page 61 and 62:
master regulator of the cell cycle
Page 63 and 64:
Work from several groups has shown
Page 65 and 66:
chromatin condensation, drop in pH,
Page 67 and 68:
Figure 23. A pathway leading to the
Page 69 and 70:
Excessive necrotic death in cells o
Page 71 and 72:
implantation, and similar processes
Page 73 and 74:
normal cells in the surroundings. T
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
A bicistronic retroviral vector (Ha
Page 81 and 82:
C. Antisense ras gene transfer for
Page 83 and 84:
equal to 6.0 showed S1 hyperreactiv
Page 85 and 86:
protein (e.g. Smith et al, 1995; Fo
Page 87 and 88: transduced primary mouse fibroblast
Page 89 and 90: IL-1 - receptor antagonist protein
Page 91 and 92: p53 lung cancer retroviru s MHC cla
Page 93 and 94: Gene Therapy and Molecular Biology
Page 95 and 96: designed by immunization with porti
Page 97 and 98: Isolation of an RNA aptamer that ca
Page 99 and 100: induction of human apoE in neonate
Page 101 and 102: atrium in heart, endothelial cells
Page 103 and 104: which eliminated tumors in small an
Page 105 and 106: C. Transfer of other genes against
Page 109 and 110: significant reduction in neointima
Page 111 and 112: (Prehn et al, 1996); this implies a
Page 113 and 114: B. Approaches to gene therapy of RA
Page 115 and 116: of human immunoglobulin and antigen
Page 117 and 118: A. Etiology and mechanisms of destr
Page 121 and 122: However, CsA also inhibits the acti
Page 123 and 124: The peptide kinin, after binding to
Page 125 and 126: intake when administered to adrenal
Page 127 and 128: Introgen Therapeutics (Austin and H
Page 129 and 130: When a subfragment of only 513 bp o
Page 131 and 132: Armentano D, Zabner J, Sacks C, Soo
Page 133 and 134: Brady HJM, Miles CG, Pennington DJ,
Page 135 and 136: Chen J, Stickles RJ, Daichendt KA (
Page 137: Day ML, Wu S, Basler JW (1993) Pros
Page 141 and 142: Giovannangeli C, Perrouault L, Escu
Page 143 and 144: the neoplastic phenotype by replace
Page 145 and 146: integrate in a site-specific fashio
Page 147 and 148: Li R, Waga S, Hannon GJ, Beach D, S
Page 149 and 150: adiation-induced apoptosis in the g
Page 151 and 152: Nakaya T, Iwai S, Fujinaga K, Sato
Page 153 and 154: Polyak K, Xia Y, Zweier JL, Kinzler
Page 155 and 156: macrophages from simian immunodefic
Page 157 and 158: intimal hyperplasia in a rat caroti
Page 159 and 160: Trono D, Feinberg MB, Baltimore D (
Page 161 and 162: Wattiaux R, Jadot M, Warnier-Pirott
Page 163 and 164: similar to mammalian interleukin-1
Page 167 and 168: 24. Gene Marking /Infectious Diseas
Page 169 and 170: Drug 50. Gene Therapy /Phase I /Can
Page 171 and 172: 76. Gene Therapy /Phase I /Cancer /
Page 173 and 174: 99. Gene Therapy /Phase II /Cancer
Page 175 and 176: 120. Gene Therapy /Phase I /Monogen
Page 179 and 180: cancer not specified) /Immunotherap
show all

01. Gene therapy Boulikas.pdf - Gene therapy & Molecular Biology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?